OLMA - NASDAQ
Olema Pharmaceuticals, Inc.
$10.51
-1.7%Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
At a Glance
Live Snapshotolma
Other Non-Current Assets
Last Annual Value
16.83M
3-Year CAGR
82%
5-Year CAGR
101%
10-Year CAGR
137%
Olema Pharmaceuticals, Inc. Competitors Analysis of Other Non-Current Assets
| Company | Other Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Olema Pharmaceuticals, Inc. NASDAQ:OLMA | 16.83M | 32.9% | 99.0% | N/A | |
 KalVista Pharmaceuticals, Inc. NASDAQ:KALV | 2.37M | 181.7% | 63.9% | N/A | |
 REGENXBIO Inc. NASDAQ:RGNX | 4.61M | -15.1% | -15.5% | 22.1% | |
 Prothena Corporation plc NASDAQ:PRTA | 482.00K | -59.4% | -32.1% | -22.6% | |
 Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 855.00K | 112.6% | 29.4% | -8.2% | |
 Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | 29.37M | 228.6% | N/A | 51.5% | |
 Verastem, Inc. NASDAQ:VSTM | 6.11M | 8.2% | 71.7% | 20.9% | |
 Absci Corporation NASDAQ:ABSI | 1.44M | -18.5% | -39.8% | N/A | |
 Ventyx Biosciences, Inc. NASDAQ:VTYX | 1.03M | -1.3% | 76.7% | N/A | |
 4D Molecular Therapeutics, Inc. NASDAQ:FDMT | 120.57M | 460.7% | 188.6% | N/A | |
 Gossamer Bio, Inc. NASDAQ:GOSS | 408.00K | -12.9% | -17.7% | N/A |
Olema Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your OLMA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.